These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 17465499)

  • 1. CCL2-2518 A/G and CCR2 190 A/G do not influence the outcome of hepatitis C virus infection in the Spanish population.
    Montes-Cano MA; Garcia-Lozano JR; Aguilar-Reina J; Romero-Gomez M; Barroso N; Nunez-Roldan A; Gonzalez-Escribano MF
    World J Gastroenterol; 2007 Apr; 13(15):2187-92. PubMed ID: 17465499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.
    Sagnelli E; Pisaturo M; Stanzione M; Messina V; Alessio L; Sagnelli C; Starace M; Pasquale G; Coppola N
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1174-1180.e11. PubMed ID: 23591280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between the Genetic Polymorphisms of
    Shao LN; Zhou SH; Wang N; Zhang ST; Liu M
    Immunol Invest; 2022 Jul; 51(5):1182-1197. PubMed ID: 33902378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
    Zimmermann T; Hueppe D; Mauss S; Buggisch P; Pfeiffer-Vornkahl H; Grimm D; Galle PR; Alshuth U
    J Gastrointestin Liver Dis; 2016 Mar; 25(1):15-24. PubMed ID: 27014750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing.
    Cheng WS; Roberts SK; McCaughan G; Sievert W; Weltman M; Crawford D; Rawlinson W; Marks PS; Thommes J; Rizkalla B; Yoshihara M; Dore GJ;
    J Hepatol; 2010 Oct; 53(4):616-23. PubMed ID: 20619475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-C chemokine receptor 2 and C-C chemokine receptor 5 genotypes in patients treated for chronic hepatitis C virus infection.
    Dorak MT; Folayan GO; Niwas S; van Leeuwen DJ; Yee LJ; Tang J; Kaslow RA
    Immunol Res; 2002; 26(1-3):167-75. PubMed ID: 12403355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCR5 promoter polymorphism influences the interferon response of patients with chronic hepatitis C in Japan.
    Konishi I; Horiike N; Hiasa Y; Michitaka K; Onji M
    Intervirology; 2004; 47(2):114-20. PubMed ID: 15192276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies.
    Marotta P; Bailey R; Elkashab M; Farley J; Feinman SV; Peltekian K; Poliquin M; Witt-Sullivan H; Rampakakis E; Drolet M; Cooper C
    Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):597-609. PubMed ID: 26851949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2007 Nov; 79(11):1686-95. PubMed ID: 17854035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up].
    Seydi M; Morlat P; Bonnet F; Rambeloarisoa J; Bernard N; Lacoste D; Bonarek M; Trimoulet P; Ramanampamonjy R; Lafon ME; Dramé M; Beylot J
    Rev Med Interne; 2005 Apr; 26(4):280-7. PubMed ID: 15820563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.
    Promrat K; McDermott DH; Gonzalez CM; Kleiner DE; Koziol DE; Lessie M; Merrell M; Soza A; Heller T; Ghany M; Park Y; Alter HJ; Hoofnagle JH; Murphy PM; Liang TJ
    Gastroenterology; 2003 Feb; 124(2):352-60. PubMed ID: 12557141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.
    Carrión JA; Navasa M; García-Retortillo M; García-Pagan JC; Crespo G; Bruguera M; Bosch J; Forns X
    Gastroenterology; 2007 May; 132(5):1746-56. PubMed ID: 17484872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong.
    Yuen MF; Lai CL
    Intervirology; 2006; 49(1-2):96-8. PubMed ID: 16166796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country.
    Hlaing NK; Banerjee D; Mitrani R; Arker SH; Win KS; Tun NL; Thant Z; Win KM; Reddy KR
    World J Gastroenterol; 2016 Nov; 22(43):9613-9622. PubMed ID: 27920482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTPN22 C1858T polymorphism and the outcome of hepatitis C virus infection.
    Montes-Cano MA; García-Lozano JR; Aguilar-Reina J; Romero-Gómez M; Barroso N; Nuñez-Roldán A; Martín J; González-Escribano MF
    Viral Immunol; 2008 Dec; 21(4):491-4. PubMed ID: 19115939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and clinical significance of GB virus type C/hepatitis G virus coinfection in patients with chronic hepatitis C undergoing antiviral therapy.
    Hofer H; Aydin I; Neumueller-Guber S; Mueller C; Scherzer TM; Staufer K; Steindl-Munda P; Wrba F; Ferenci P
    J Viral Hepat; 2011 Jul; 18(7):513-7. PubMed ID: 20565572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3.
    Abbas Z; Moatter T; Hussainy A; Jafri W
    World J Gastroenterol; 2005 Nov; 11(42):6656-61. PubMed ID: 16425360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-density lipoprotein receptor genetic polymorphism in chronic hepatitis C virus Egyptian patients affects treatment response.
    Naga M; Amin M; Algendy D; Elbadry A; Fawzi M; Foda A; Esmat S; Sabry D; Rashed L; Gabal S; Kamal M
    World J Gastroenterol; 2015 Oct; 21(39):11141-51. PubMed ID: 26494968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.